RECEIVED **CENTRAL FAX CENTER**

JUL 17 2008

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING RELECTION OVER A "PRIOR" PATENT ALEX-P01-054 ALE	U.S. Patent a Inder the Paperwork Reduction <u>Act of 1996, no persons are required to respond to a collecti</u>	and Trademark Office; U.S. DEPARTMENT OF COMMERCION of Information unless it displays a valid OMB control number
polication No.: 10/006,593 ed: December 5, 2001 ir: RATIONALLY DESIGNED ANTIBODIES ir: Rational polication with antibodies and the profession of the full statutory term of prior patent to presently shortened and yellow profession and the landing upon the profession patent to profession and the brinding upon the profession and the landing upon the profession and the profession and the landing upon the profession and the p	TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATEN	ITING Docket Number (Optional)
illed: December 5, 2001 Or. RATIONALLY DESIGNED ANTIBODIES The owner*. Alexion Pharmaceuticals, Inc. of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent is only 38,917. In the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened yany terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable rily for and during such period treat it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and to binding upon the grantee, as successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant splication that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior attent. To the term of said prior patent is presently shortened by any terminal disclaimer, in the event that said prior patent is received to the terminal prior the said prior patent is performed to the expiration of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior attent. The prior patent is part of the prior patent is stationally disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexemination certificate; is reliabled; or it is stationally disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexemination certificate; is reliabled; or it is not study of the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statement and on Information and behalf of a business/organization or any patent issued t	n re Application of: Bowdish et al.	
for: RATIONALLY DESIGNED ANTIBODIES The owner*. Alexion Pharmaceuticals, Inc. Inc.	pplication No.: 10/006,593	
the owner*. Alexion Pharmaceuticals, Inc	iled: December 5, 2001	
instant application hereby disclaims, except us provided below, the terminal part of the statutory term of any patent granted on the instant application hereby disclaims, except us provided below, the terminal part of the statutory term of prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable inly for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and its binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that the owner does not disclaim the terminal part of the term of any patent granted on the instant application that of the extent of said prior patent is presently shortened by any terminal disclaimer, in the event that said prior patent ster. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as the term of said prior patent is presently shortened by any terminal disclaimer, in the event that said prior patent after. In the statutority disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reasonimation certificate; is reissued; or is nany manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization of the full statutory term as presently shortened by any terminal disclaimer. I hereby declare that all statements made herein of my own knowledge are true and that all statements and be informed to be true; and further that these statements were made with the k	or RATIONALLY DESIGNED ANTIBODIES	
aster. as the term of said prior patent is presently shortened by any terminal disclaimer, in the event that said prior patent ater: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and that its owned are punishable by fine or Imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. X The undersigned is an attorney or agent of record. Reg. No. July 17, 2008 Date July 17, 2008 Date July 17, 2008 Telephone Number X Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	nstant application hereby disclaims, except as provided below, the terminal prestant application which would extend beyond the expiration date of the full status the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as it by any terminal disclaimer. The owner hereby agrees that any patent so grainly for and during such period that it and the prior patent are commonly own the instant application and is binding upon the grantee, its successors or an making the above disclaims of the owner does not disclaim the terminal provided the status of the full statutory terminal to the owner does not disclaim the terminal provided the status of the full statutory terminal provided the status of the status	art of the statutory term of any patent granted on the tutory term of prior patent No. 7,396,917 the term of said prior patent is presently shortened inted on the Instant application shall be enforceable used. This agreement runs with any patent granted assigns. art of the term of any patent granted on the instant as defined in 35 U.S.C. 154 and 173 of the prior
Jennifer K. Holmes, Ph.D., J.D. Typed or printed name (617) 951-7933 Telephone Number X Terminal discialmer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner).	ater: expires for failure to pay a maintenance fee; Is held unenforceable; Is found invalid by a court of competent jurisdiction; Is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1. has all claims canceled by a remaintation certificate; Is reissued; or Is in any manner terminated prior to the expiration of its full statutory term in any manner terminated prior to the expiration of its full statutory term in the control of the statutory term in the control of the control of the statutory term in the control of the undersigned is empowered to act on behalf of the business of the control of	as presently shortened by any terminal disclaimer. ration, partnership, university, government agency, ess/organization. are true and that all statements made on information ade with the knowledge that willful false statements. Section 1001 of Title 18 of the United States Code alion or any patent issued thereon. 46,778
Typed or printed name (617) 951-7933 Telephone Number X Terminal discialmer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner).	SigNature SigNature	Date
(617) 951-7933 Telephone Number X Terminal discialmer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner).		
Telephone Number X Terminal discialmer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal discialmer is signed by the assignee (owner).	Typed or or	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PYO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	WARNING: Information on this form may become pu	iblic. Credit card information should not ation and authorization on PTO-2038.
FUNITE TOTALISM HIBY OF USES OF HIBMING CHEST STREET, STORY III STORY	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed Form PTO/SB/96 may be used for making this certification. See MPEP § 32	by the assignee (owner). 24.
1 hereby cartify that this paper (along with any paper referred to as being attached or enclosed) is being standard by facsimile to the Parent and 1 for 2014		07/18/2000 BCHAIL